Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga·08/19/2025 17:32:01
Listen to the news
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
- Dividend Yield: 4.62%
- UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $25 to $24 on Aug. 8, 2025. This analyst has an accuracy rate of 66%.
- Stifel analyst Jonathan Block maintained a Hold rating and cut the price target from $19 to $17 on Aug. 8, 2025. This analyst has an accuracy rate of 73%.
- Recent News: On Aug. 7, Dentsply Sirona reported better-than-expected second-quarter EPS and sales.
- Benzinga Pro’s real-time newsfeed alerted to latest XRAY news.
Bristol-Myers Squibb Company (NYSE:BMY)
- Dividend Yield: 5.15%
- Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $51 to $47 on Aug. 1, 2025. This analyst has an accuracy rate of 70%.
- Morgan Stanley analyst Terence Flynn maintained an Underweight rating and cut the price target from $36 to $34 on July 10, 2025. This analyst has an accuracy rate of 63%.
- Recent News: On Aug. 18, the FDA granted Breakthrough Therapy Designation to Systimmune and Bristol Myers Squibb’ Izalontamab Brengitecan for previously treated advanced EGFR-mutated non-small cell lung cancer.
- Benzinga Pro's real-time newsfeed alerted to latest BMY news
Medtronic plc (NYSE:MDT)
- Dividend Yield: 3.06%
- Mizuho analyst Anthony Petrone maintained an Outperform rating and raised the price target from $98 to $100 on July 16, 2025. This analyst has an accuracy rate of 64%.
- Citigroup analyst Joanne Wuensch maintained a Buy rating and increased the price target from $98 to $99 on July 9, 2025. This analyst has an accuracy rate of 73%.
- Recent News: On Aug. 19, Medtronic topped first-quarter earnings expectations. Additionally, the company announced new board appointments following engagement with Elliott Management.
- Benzinga Pro’s real-time newsfeed alerted to latest MDT news
Read More:
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.